“We are delighted with the robust sales growth in the third quarter, during which we have continued to increase commercial capacity and deliver CARVYKTI to more multiple myeloma patients around the ...

Arcellx has shared several data cuts on anito-cel, a CAR-T being developed with Gilead’s Kite Pharma to treat relapsed or ...

Truist raised the firm’s price target on Arcellx (ACLX) to $136 from $87 and keeps a Buy rating on the shares after its Q3 results. The ...

Legend has become a force partnering with Johnson & Johnson on CAR-T multiple myeloma therapy Carvykti. Thanks to an FDA approval in second-line multiple myeloma, Carvykti’s sales, as booked by J&J, ...

The CAR-T cell therapy Carvykti has been shown to be effective among patients outside the confines of a clinical trial.

Alan Bash is joining Legend Biotech as its president of Carvykti, an unconventional, newly-created role to oversee the ...

Truist Securities analyst Asthika Goonewardene in an investor note said data for anito-cel—particularly its safety ...

Legend Biotech (NASDAQ:LEGN) is scheduled to announce Q3 earnings results on Tuesday, November 12th, before market open. The consensus EPS Estimate is -$0.57 and the consensus Revenue Estimate is $146 ...

An FDA announcement last year of an investigation into the risk of patients developing secondary cancers following the ...

In this newly created role, Mr. Bash will be responsible for managing the continued growth of CARVYKTI ®, overseeing Legend Biotech’s commercial, technical operations, and quality functions of ...

The companies’ CAR-T seemed to cause fewer movement disorders in a multiple myeloma trial than J&J's Carvykti has in other ...

AstraZeneca is under scrutiny in China — as its top executive there and other personnel are being investigated by authorities ...